Anti-TIGIT therapies for solid tumors: a systematic review

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

(2022) Karl L. Banta et al.   IMMUNITY

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

(2022) Byoung Chul Cho et al.   LANCET ONCOLOGY

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model

(2022) Songlin Mu et al.   Clinical and Translational Medicine

111P Interim biomarker analysis of a phase Ib/II study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE)

(2022) G. Sarikonda et al.   ANNALS OF ONCOLOGY

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity

(2022) Zhenwei Zhong et al.   Scientific Reports

Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study

(2021) Fiona Blackhall et al.   Journal of Thoracic Oncology

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

(2021) Zhouhong Ge et al.   Frontiers in Immunology

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

(2021) J. Niu et al.   ANNALS OF ONCOLOGY

A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

(2021) Niharika B. Mettu et al.   CLINICAL CANCER RESEARCH

A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment

(2021) Jie Wen et al.   Scientific Reports

Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma)

(2020) Yu Sun et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy

(2020) Hyung-seung Jin et al.   Cancer Immunology Research

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer

(2019) Niclas C. Blessin et al.   DISEASE MARKERS

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

(2019) Martin Reck et al.   EUROPEAN JOURNAL OF CANCER

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

(2019) Edward B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

(2019) Andrew A. Davis et al.   Journal for ImmunoTherapy of Cancer

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

(2017) Nicholas A. Manieri et al.   TRENDS IN IMMUNOLOGY

Reversing T-cell Dysfunction and Exhaustion in Cancer

(2016) H. M. Zarour   CLINICAL CANCER RESEARCH

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy

(2016) S. J. Blake et al.   CLINICAL CANCER RESEARCH

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

(2015) Joe-Marc Chauvin et al.   JOURNAL OF CLINICAL INVESTIGATION

TIGIT predominantly regulates the immune response via regulatory T cells

(2015) Sema Kurtulus et al.   JOURNAL OF CLINICAL INVESTIGATION

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses

(2014) Nicole Joller et al.   IMMUNITY

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR

(2013) Noa Stanietsky et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The TIGIT/CD226 Axis Regulates Human T Cell Function

(2012) E. Lozano et al.   JOURNAL OF IMMUNOLOGY

Vstm3 is a member of the CD28 family and an important modulator of T-cell function

(2011) Steven D. Levin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY